Screener
Kura Oncology KURA Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The source filing: Kura Oncology’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219481
| Line item | March 31, 2026 | December 31,2025 |
|---|---|---|
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $7,043 | $5,017 |
| Accrued expenses and other current liabilities | 45,466 | 61,697 |
| Current operating lease liabilities | 1,283 | 1,277 |
| Current portion of contract liabilities | 47,704 | 48,983 |
| Total current liabilities | 101,496 | 116,974 |
| Long-term debt, net | 9,749 | 9,711 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Kura Oncology's accrued expenses?
- Kura Oncology (KURA) reported accrued expenses of $45.47M in Q1 2026.
- What is the long-term trend for Kura Oncology's accrued expenses?
- Over 2 years (2021 to 2025), Kura Oncology's accrued expenses has grown at a 90.8% compound annual growth rate (CAGR), from $16.96M to $61.7M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Kura Oncology's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude